Skip to content

Study of Laparoendoscopic Single Site Hysterectomy in Benign and Preinvasive Uterine Disease

Prospective Randomized Comparison of Single-port and Three-port Laparoscopic Assisted Vaginal Hysterectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01679548
Enrollment
424
Registered
2012-09-06
Start date
2012-11-23
Completion date
2019-06-11
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign or Preinvasive Uterine Disease

Keywords

LESS, Benign uterine disease, LAVH

Brief summary

To compare the efficacy between single-port and three-port laparoscopic assisted vaginal hysterectomy in patients with benign or preinvasive uterine disease

Detailed description

This study intended to conduct a randomized trial to determine whether LESS LAVH has a faster recovery rate than three-port LAVH.

Interventions

LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.

PROCEDUREThree-port LAVH

Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patient who undergo laparoscopic assisted vaginal hysterectomy due to following gynecologic disease 1. uterine leiomyoma 2. uterine adenomyosis 3. Endometrial hyperplasia 4. cervical intraepithelial neoplasia including carcinoma in situ 5. Dysfunctional uterine bleeding 6. Other benign gynecologic disease requiring hysterectomy * American Society of Anesthesiologists Physical Status classification I-II * Patient who have signed an written informed consent

Exclusion criteria

* Uncontrolled medical disease * Active infectious disease * Previous pelvic radiation therapy * Patient who requiring further procedure excluding hysterectomy, unilateral or bilateral salpingooophorectomy / salpingectomy / oophorectomy * Patient who undergoes subtotal hysterectomy * Patient who have other pain source excluding gynecologic disease * Pregnancy and lactating woman

Design outcomes

Primary

MeasureTime frameDescription
postoperative hospital staywithin 1 week after surgeryThe primary endpoint was to compare average length of postoperative hospital stay and the ratio of patients discharged within 2 days after surgery between LESS and conventional groups.

Secondary

MeasureTime frameDescription
postoperative painwithin 1 week after surgeryPostoperative pain was recorded using the Visual Analog Pain Scale (VAS), scored from 1 to 10 (0 is no pain and 10 is agonizing pain)
postoperative analgesics requirementwithin 1 week after surgeryWhenever patients requested additional analgesia, they were administered parenterally.
operating time1 day (immediately ater surgery)skin to skin operation time was recorded
Transfusion requirement and amountwithin 1 week after surgeryTransfusion requirement and amount were recorede
intra and postoperative complicationwithin 1 months after surgeryintra and post operative complications were recorede

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026